ArticleFrontiers in immunology2025
Development and validation of a novel nomogram for predicting outcomes in advanced lung cancer patients treated beyond progression with immune checkpoint inhibitors.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Standardized management of lung cancer (LC) progressing post-immunotherapy remains challenging, with debated clinical benefits of treatment beyond progression (TBP). We evaluated the efficacy of continued immune checkpoint inhibitors (ICIs) and developed a pharmacologically guided nomogram to optimize TBP decision-making. Methods: This retrospective analysis of 153 LC patients undergoing post-progression ICIs continuation identified significant predictors via the least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox analysis. A nomogram predicting overall survival (OS) and progression-free survival (PFS) was constructed and validated using time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: Treatment regimen, Eastern Cooperative Oncology Group (ECOG) performance status, efficacy evaluation, lymph node metastasis, and liver metastasis independently predicted OS, while liver metastasis and efficacy evaluation influenced PFS. The nomogram demonstrated robust discrimination (OS C-index=0.700; PFS C-index=0.599) with area under the curve (AUC) values of 0.786/0.777/0.705 (OS) and 0.621/0.638/0.630 (PFS) at 6/12/24 months. DCA confirmed the clinical utility of the OS nomogram. Patients were stratified into high- and low-risk groups based on optimal cutoff values, and risk stratification revealed significant survival differences (p<0.01). Conclusion: This validated nomogram provides a clinically actionable tool to identify patients benefiting from sustained ICIs exposure, enabling pharmacologically informed TBP strategies while minimizing futile drug exposure. Future prospective multicenter studies should validate utility across diverse pharmacogenomic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.